

AROA AWARDED REG SKIN GRAFTING PRODUCTS AGREEMENT WITH PREMIER, INC.

Highlights

- AROA has been awarded a group purchasing agreement for its Myriad™ and Symphony™ products, with Premier, Inc. – a leading U.S. healthcare improvement company.
 - The agreement provides approximately 4,400 US hospitals and healthcare systems, access to these patented soft tissue reconstruction and complex wound healing products.
 - Premier members will be able to access Myriad and Symphony products beginning 1 March 2023.
-

Aroa Biosurgery Limited (ASX: ARX, 'AROA or the 'Company') is pleased to announce that it has been awarded a group purchasing agreement for the regenerative skin grafting products category, with Premier, Inc.

Effective March 1, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for AROA's regenerative healing products, Myriad Matrix™, Myriad Morcells™ and Symphony.

Myriad Matrix and Myriad Morcells are based on AROA ECM technology and designed for soft tissue reconstruction and complex wounds.

Symphony combines AROA ECM with hyaluronic acid and is designed to support healing and reduce time to wound closure, particularly in patients where healing is severely impaired or compromised due to concurrent disease.

Commenting on the new agreement, AROA CEO Dr Brian Ward says "We're very pleased to have this agreement with Premier in place. AROA now holds supply agreements with all four of the largest GPOs in the US. This helps to ensure that over 90% of hospitals in the United States have access to our products through their primary GPO."

Premier is a leading healthcare improvement company, uniting an alliance of more than 4,400 U.S. hospitals and health systems and approximately 250,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost.

< ENDS >

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

About Aroa Biosurgery:

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine forestomach. AROA has six



patented product families selling in the US based on its AROA ECM technology, targeting chronic wounds, hernia, soft tissue and breast reconstruction. AROA's products have been used in more than 5.8 million procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio. AROA has regulatory approvals in more than 50 countries. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX:ARX). www.aroabio.com/

Contact Details

Sarah Tora
Corporate Communications Manager
+64 21 531043
sarah.tora@aroabio.com